CA3217487A1 - Heterodimeric antibodies and antigen-binding fragment thereof - Google Patents
Heterodimeric antibodies and antigen-binding fragment thereof Download PDFInfo
- Publication number
- CA3217487A1 CA3217487A1 CA3217487A CA3217487A CA3217487A1 CA 3217487 A1 CA3217487 A1 CA 3217487A1 CA 3217487 A CA3217487 A CA 3217487A CA 3217487 A CA3217487 A CA 3217487A CA 3217487 A1 CA3217487 A1 CA 3217487A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid residue
- region
- polypeptide complex
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021089400 | 2021-04-23 | ||
| CNPCT/CN2021/089400 | 2021-04-23 | ||
| PCT/CN2022/088386 WO2022223016A1 (en) | 2021-04-23 | 2022-04-22 | Heterodimeric antibodies and antigen-binding fragment thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217487A1 true CA3217487A1 (en) | 2022-10-27 |
Family
ID=83721948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217487A Pending CA3217487A1 (en) | 2021-04-23 | 2022-04-22 | Heterodimeric antibodies and antigen-binding fragment thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240182576A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326772A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024517671A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117597361A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022261269A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3217487A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022223016A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202506741A (zh) * | 2023-04-06 | 2025-02-16 | 美商麥迪紐有限責任公司 | 工程化抗體 |
| AU2024381273A1 (en) * | 2023-11-14 | 2026-06-04 | Fortvita Biologics Inc. | Anti-egfr and -her3 bispecific antibody-drug conjugate and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341235C (en) * | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US9527927B2 (en) * | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| KR101813708B1 (ko) * | 2013-03-13 | 2017-12-29 | (주) 아이벤트러스 | 소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법 |
| WO2015173756A2 (en) * | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Bispecific antibodies |
| CA2980189A1 (en) * | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| KR102669686B1 (ko) * | 2015-04-28 | 2024-05-29 | 자임워크스 비씨 인코포레이티드 | 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| CA3025162A1 (en) * | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| AU2017356317A1 (en) * | 2016-11-14 | 2019-05-30 | Amgen Inc. | Bispecific or biparatopic antigen binding proteins and uses thereof |
| CN110357960A (zh) * | 2018-04-10 | 2019-10-22 | 广州爱思迈生物医药科技有限公司 | 抗体及抗体改造方法 |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG BINDING MOLECULES |
| WO2020136566A1 (en) * | 2018-12-24 | 2020-07-02 | Sanofi | Multispecific binding proteins with mutant fab domains |
| CN115093481A (zh) * | 2019-01-28 | 2022-09-23 | 正大天晴药业集团股份有限公司 | 新型双特异性cd3/cd20多肽复合物 |
| AU2020283890A1 (en) * | 2019-05-30 | 2021-12-16 | Amgen Inc. | Engineering the hinge region to drive antibody dimerization |
-
2022
- 2022-04-22 EP EP22791122.9A patent/EP4326772A4/en active Pending
- 2022-04-22 US US18/556,665 patent/US20240182576A1/en active Pending
- 2022-04-22 CN CN202280030146.3A patent/CN117597361A/zh active Pending
- 2022-04-22 CA CA3217487A patent/CA3217487A1/en active Pending
- 2022-04-22 WO PCT/CN2022/088386 patent/WO2022223016A1/en not_active Ceased
- 2022-04-22 AU AU2022261269A patent/AU2022261269A1/en active Pending
- 2022-04-22 JP JP2023565204A patent/JP2024517671A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024517671A (ja) | 2024-04-23 |
| CN117597361A (zh) | 2024-02-23 |
| EP4326772A1 (en) | 2024-02-28 |
| AU2022261269A1 (en) | 2023-11-09 |
| US20240182576A1 (en) | 2024-06-06 |
| EP4326772A4 (en) | 2025-03-05 |
| WO2022223016A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP7261307B2 (ja) | 新規二重特異性cd3/cd20ポリペプチド複合体 | |
| KR20230156079A (ko) | Cd3과 cldn6에 결합하는 이종이량체 항체 | |
| JP2022553464A (ja) | 多重特異性抗体とその製造方法および使用 | |
| CN119039441A (zh) | 与nkp30结合的抗体分子及其用途 | |
| US20230348627A1 (en) | Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof | |
| WO2023051727A1 (zh) | 结合cd3的抗体及其用途 | |
| US20250270315A1 (en) | Novel anti-sirpa antibodies | |
| WO2024131962A1 (zh) | 新型抗gprc5d抗体 | |
| WO2022223016A1 (en) | Heterodimeric antibodies and antigen-binding fragment thereof | |
| CA3180507A1 (en) | Heterodimeric proteins | |
| JP2026510833A (ja) | 抗cd28組成物 | |
| KR20260011224A (ko) | 항-cd28 x 항-enpp3 항체 | |
| WO2021190580A1 (en) | Bispecific polypeptide complexes, compositions, and methods of preparation and use | |
| TWI830124B (zh) | 具有改善的穩定性和表現的多肽複合物 | |
| WO2024027120A1 (en) | Multi-specific polypeptide complexes | |
| WO2022156687A1 (en) | Polypeptide complexes with improved stability and expression | |
| WO2024149381A1 (en) | Multi-specific polypeptide complexes | |
| WO2025026282A1 (en) | Modified type e multi-specific antibodies | |
| WO2025092987A9 (zh) | 基于Fc区的异二聚体分子及其用途 | |
| KR20240116743A (ko) | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 | |
| CN121969645A (zh) | 用于将免疫球蛋白重定向至免疫细胞的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250403 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250403 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260226 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260417 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260427 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260427 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260427 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260427 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260427 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260427 |